This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zheng, P.-P. Articles by Kros, J. M. Search for Related Content PubMed PubMed Citation Articles by Zheng, P.-P. Articles by Kros, J. M.

Low-Molecular Weight Caldesmon as a Potential Serum Marker for Glioma

Authors' Affiliations: Departments of ¹ Pathology, ² Epidemiology and Biostatistics, ³ Neurology, and ⁴ Neurosurgery, Erasmus Medical Center, Rotterdam, the Netherlands

Requests for reprints: Johan M. Kros, Department of Pathology, JNI, Erasmus Medical Center, Dr. Molewaterplein 50, 3000 DR Rotterdam, the Netherlands. Phone: 31-10-408-7905; Fax: 31-10-408-7905; E-mail: j.m.kros{at}erasmusmc.nl.

Purpose: Testing the feasibility of using the serum low-molecular weight caldesmon (l-CaD) level as a serum marker for the presence of glioma.

Experimental Design: Within a total of 230 serum samples, the l-CaD level was measured in healthy volunteers (30), patients with gliomas (57), nonglial intracranial tumors (107), and nontumor neurologic diseases (36) by ELISA. The specificity of the assay was monitored by combination of immunoprecipitation and immunoblotting.

Results: The serum level of l-CaD is significantly higher in the group of glioma patients as compared with any of the other groups (P < 0.001). The cutoff value of 45 yields optimal sensitivity and specificity of the assay (91% and 84%, respectively; area under the curve score = 0.91). The specificity of ELISA was confirmed by the immunoprecipitation/immunoblotting control experiments. There were no significant differences in serum l-CaD levels between patients with low- or high-grade gliomas.

Conclusions: The serum l-CaD level as determined by ELISA is a good discriminator between glioma patients versus patients with other intracranial tumors, other neurologic diseases, and healthy people. Prospective studies are required to test the contribution of the assay in making the diagnosis of glioma, or its feasibility for monitoring the tumor during treatment.

Key Words: glioma • neovascularization • caldesmon

This article has been cited by other articles:

				C. S. Jung, C. Foerch, A. Schanzer, A. Heck, K. H. Plate, V. Seifert, H. Steinmetz, A. Raabe, and M. Sitzer Serum GFAP is a diagnostic marker for glioblastoma multiforme Brain, December 1, 2007; 130(12): 3336 - 3341. [Abstract] [Full Text] [PDF]

				D. A. N. Mustafa, P. C. Burgers, L. J. Dekker, H. Charif, M. K. Titulaer, P. A. E. S. Smitt, T. M. Luider, and J. M. Kros Identification of Glioma Neovascularization-related Proteins by Using MALDI-FTMS and Nano-LC Fractionation to Microdissected Tumor Vessels Mol. Cell. Proteomics, July 1, 2007; 6(7): 1147 - 1157. [Abstract] [Full Text] [PDF]

				A. Hormigo, B. Gu, S. Karimi, E. Riedel, K. S. Panageas, M. A. Edgar, M. K. Tanwar, J. S. Rao, M. Fleisher, L. M. DeAngelis, et al. YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas. Clin. Cancer Res., October 1, 2006; 12(19): 5698 - 5704. [Abstract] [Full Text] [PDF]